Universal Nutriscience Private Limited completes acquisition of the Nutraceuticals business from Sanofi India Limited

Advertisements

MUMBAI, INDIA – September 30, 2021: Universal Nutriscience Pvt. Ltd. (UNS) announced today the completion of the acquisition of all assets pertaining to the Nutraceuticals business of Sanofi India Limited (SIL) through a slump sale process. UNS is a strategic partnership between Kedaara Capital (one of India’s leading private equity firms) and Universal Medicare (a pioneer in Nutraceuticals).

UNS’s vision is to build India’s leading Nutraceuticals & Wellness company through a world-class, science-driven portfolio of products, with the help of a talented and highly-engaged team. The company is backed by over three decades of expertise in manufacturing and R&D, dedicated exclusively to Nutraceuticals, including several first-to-market launches. The Board also includes highly experienced industry experts to guide the company on its mission to create India’s most admired Nutraceuticals company.

UNS has appointed Vikash Prasad as the CEO of the business. Vikash brings with him over two decades of experience in Consumer Health across prominent multinational corporations such as GlaxoSmithKline, Sanofi and Abbott. Prior to UNS, Vikash served as the MD & General Manager of the Nutrition business for Abbott in India. He has also previously served as the General Manager of Sanofi’s Consumer Healthcare business in Vietnam.

Vikash Prasad, CEO, UNS said, “I am excited to be leading this ambitious new venture with well-known Nutraceutial brands acquired from Sanofi, and inherit an outstanding and highly professional sales force and leadership team. We are committed to building one of the most admired integrated Nutraceutical platforms in India, backed by highly committed stakeholders. We are also fortunate to have the counsel and mentorship of two of the foremost leaders in the Indian pharmaceutical industry, Mr Annaswamy Vaidheesh (Ex-MD of GSK India) and Dr Shailesh Ayyangar (Ex-MD of Sanofi India)”.

Commenting on the occasion, Dr. Shailesh Ayyangar, Chairman of the Board of Directors – UNS said, “The recent pandemic has exposed the vulnerability of the population to unexpected health hazards. Besides therapeutics and vaccines, there is mounting scientific evidence of the positive effects of nutritional supplements to enhance quality of life and augment management of chronic disease conditions across all ages. I am delighted that UNS is focused exclusively on Nutraceuticals and has the necessary resources, the drive and the vision to become the country’s leading Nutraceutical and Wellness company.”

The complete Nutraceutical portfolio consisting of 16 brands, including market leaders such as Seacod, ECod, CoQ, Primosa, Collaflex, along with most of the employees engaged in the marketing and distribution of these brands, have been seamlessly transferred to UNS effective 30th September 2021.

Universal Nutriscience Pvt. Ltd. is a strategic partnership between Kedaara Capital (one of India’s leading private equity firms) and Universal Medicare (one of the pioneers in Nutraceuticals). The company will also benefit from the experience and expertise of well-known industry experts such as Dr. Shailesh Ayyangar and Mr. Annaswamy Vaidheesh who will join the Board. In addition, the management team is drawn from outstanding talents in the healthcare industry.

Kedaara Capital is an operationally oriented private equity firm pursuing control and minority investment opportunities in India. It currently advises and manages over ~US$ 3.6 billion across 3 funds that have invested in several market leading businesses across a variety of sectors including consumer, financial services, pharma/healthcare, business services and industrials. Kedaara’s operating partner model enables businesses to realize their full potential. Kedaara was co-founded by Manish Kejriwal, Sunish Sharma and Nishant Sharma and combines the strengths of a well-networked, highly experienced local investing and operating team, with the experience of their strategic partner, Clayton, Dubilier & Rice, a global private equity firm whose investment model blends financial skills with operating expertise.

UMPL is one of the pioneers in Nutraceuticals in India and possesses a deep understanding of the segment, including the portfolio under consideration. The company continues to have strong brand equity with doctors and other healthcare professionals, and is well-reputed for its pioneering efforts in the category, as well as for the science behind its products. UMPL’s R&D and innovation track record will be a key driver of the new launch pipeline for Universal NutriScience.



Categories: Corporate M&A

Tags: , , , , ,

Leave a Reply

%%footer%%